作者: Sihan Wu , Wenbo Zhu , Guangmei Y
DOI: 10.5772/52672
关键词: microRNA 、 Anaplastic glioma 、 Oncology 、 Radiation therapy 、 Brain tumor 、 Survival rate 、 Medicine 、 Surgical resection 、 Median survival 、 Internal medicine 、 Glioma
摘要: Malignant glioma (MG), consisting of anaplastic (AA, WHO grade III) and glioblas‐ tomamultiforme (GBM, IV, 60-70%), is the most common destructive brain tumor [1]. Despite systemic treatment, surgical resection followed by radiotherapy che‐ motherapy, prognosis patients with GBM remains poor a median survival 12 to 15 months 5-year rate 9.8% [2, 3]. The dismal outcome fuels need understand molecular basis gliomagenesis identify novel therapeutic targets for MG treatment.